Lowest dose interleukin-2 immunotherapy.
Smith
K A
KA
Department of Medicine, Dartmouth Medical School, Hanover, NH 03755-3833.
D000163:Acquired Immunodeficiency Syndrome / Q000628:therapy; D016026:Bone Marrow Transplantation; D006801:Humans; D006968:Hypersensitivity, Delayed; D007376:Interleukin-2 / Q000009:adverse effects / Q000502:physiology / Q000627:therapeutic use*; D007694:Killer Cells, Natural / Q000187:drug effects / Q000276:immunology; D015440:Leprosy, Lepromatous / Q000628:therapy; D009369:Neoplasms / Q000628:therapy; D015375:Receptors, Interleukin-2 / Q000378:metabolism; D013329:Structure-Activity Relationship
D007376:Interleukin-2; D015375:Receptors, Interleukin-2